Skip to main content

ImmunoGen axes 75% of staff to fund new clinical trial

After its Phase 3 trial failed, ImmunoGen has opted to continue testing its ovarian cancer drug in a subgroup of patients with high rates of a protein called folate receptor alpha.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.